Your browser doesn't support javascript.
Coronavirus Disease 2019 Messenger RNA Vaccine Immunogenicity in Immunosuppressed Individuals.
Collier, Ai-Ris Y; Yu, Jingyou; McMahan, Katherine; Liu, Jinyan; Atyeo, Caroline; Ansel, Jessica L; Fricker, Zachary P; Pavlakis, Martha; Curry, Michael P; Jacob-Dolan, Catherine; Patel, Het; Sellers, Daniel; Barrett, Julia; Rowe, Marjorie; Ahmad, Kunza; Gompers, Annika; Aguayo, Ricardo; Chandrashekar, Abishek; Alter, Galit; Hacker, Michele R; Barouch, Dan H.
  • Collier AY; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
  • Yu J; Harvard Medical School, Boston, Massachusetts, USA.
  • McMahan K; Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
  • Liu J; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
  • Atyeo C; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
  • Ansel JL; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
  • Fricker ZP; Harvard Medical School, Boston, Massachusetts, USA.
  • Pavlakis M; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, Massachusetts, USA.
  • Curry MP; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
  • Jacob-Dolan C; Harvard Medical School, Boston, Massachusetts, USA.
  • Patel H; Transplant Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
  • Sellers D; Harvard Medical School, Boston, Massachusetts, USA.
  • Barrett J; Transplant Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
  • Rowe M; Harvard Medical School, Boston, Massachusetts, USA.
  • Ahmad K; Transplant Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
  • Gompers A; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
  • Aguayo R; Harvard Medical School, Boston, Massachusetts, USA.
  • Chandrashekar A; Transplant Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
  • Alter G; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
  • Hacker MR; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
  • Barouch DH; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
J Infect Dis ; 225(7): 1124-1128, 2022 04 01.
Article in English | MEDLINE | ID: covidwho-1774388
ABSTRACT
Individuals on immunosuppressive (IS) therapy have increased mortality from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and delayed viral clearance may lead to new viral variants. IS therapy reduces antibody responses following coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccination; however, a comprehensive assessment of vaccine immunogenicity is lacking. Here we show that IS therapy reduced neutralizing, binding, and nonneutralizing antibody functions in addition to CD4 and CD8 T-cell interferon-γ responses following COVID-19 mRNA vaccination compared to immunocompetent individuals. Moreover, IS therapy reduced cross-reactivity against SARS-CoV-2 variants. These data suggest that the standard COVID-19 mRNA vaccine regimens will likely not provide optimal protection in immunocompromised individuals.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: J Infect Dis Year: 2022 Document Type: Article Affiliation country: Infdis

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: J Infect Dis Year: 2022 Document Type: Article Affiliation country: Infdis